Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual growth-oriented stocks instead of relying on index funds.
Copyright 2024 – Finance News Network
Source: Finance News Network
19 Mar 2025 - Michael Fazzini, Sales and Distribution Executive at Capital Prudential, discusses the company's strategy.
Read More12 May 2021 - Galan Lithium (ASX:GLN) Managing Director Juan Pablo Vargas de la Vega provides an update on they company's key Hombre Muerto lithium brine project in the Catamarca province of Argentina.
Read More25 Aug 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses reporting season and the lack of guidance from companies, cyclical businesses and M&A activity in the Energy sector.
Read More31 Mar 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO,Giles Bourne, talks about the company's 1:1 non-renounceable rights issue, the need to fund its technology through to commercialisation, independent validation of its RPCVD technology and its response to COVID-19.
Read More20 Sep 2024 - Prime Financial Group Limited (ASX:PFG) Managing Director, CEO and Chairman Simon Madder provides an update on the company, discussing drivers behind FY24 performance, the acquisitions of Altor Capital and Equity Plan Management, and outlook.
Read More16 Sep 2024 - Quantum Brilliance CEO Mark Luo discusses how his company is pioneering quantum computing with synthetic diamonds, offering a miniaturised and energy-efficient alternative. He highlights the company's rapid growth since its spin-out from the Australian National University, its unique approach to quantum technology and the enormous commercial potential of quantum at the edge.
Read More13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s blockbuster insomnia drug Ambien and focus for 2020.
Read More25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More29 Feb 2024 - Mitch Thomas - CFO - Latin Resources (ASX:LRS) is exploring and developing sustainable minerals in Australia and Latin America to provide the planet with environmentally friendly products.
Read More
